Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-06-06Clinical Trial Update: Phase I Study of HSK46575 in Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 1]
This clinical trial update describes a Phase I study evaluating HSK46575 in patients with metastatic castration-resistant prostate cancer; r…
-
CLINICAL_TRIALS research · 2025-05-30Clinical Trial Update: ProsTIC Registry of Men Treated With PSMA Theranostics
This entry provides an update on the ProsTIC Registry, a study of men treated with PSMA theranostics for prostate cancer, which is currently…
-
CLINICAL_TRIALS research · 2025-05-21Clinical Trial Update: A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC [Phase 1, Phase 2]
This clinical trial entry updates on a Phase 1/2 study of 177Lu-NYM032 Injection for metastatic castration-resistant prostate cancer, noting…
-
CLINICAL_TRIALS research · 2025-05-15Clinical Trial Update: A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas [Phase 1, Phase 2]
Clinical trial update for Tulmimetostat DZR123 (CPI-0209) in adults with advanced solid tumors and various lymphomas. The study is in Phase …
-
CLINICAL_TRIALS research · 2025-05-14Clinical Trial Update: Radiotherapy Combined With Fluzopanib and Abiraterone Acetate Tablets (II) Treatment for mCRPC [Phase 2]
Phase 2 clinical trial evaluating radiotherapy in combination with fluzopanib and abiraterone acetate for metastatic castration-resistant pr…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-05-07Clinical Trial Update: Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial [Phase 2]
Phase 2 clinical trial investigating the combination of cabozantinib and atezolizumab for metastatic castration-resistant prostate cancer is…
-
CLINICAL_TRIALS research · 2025-05-04Clinical Trial Update: A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating the combination of copanlisib and rucaparib in metastatic castration-resistant prostate cancer; the…
-
CLINICAL_TRIALS research · 2025-04-20Clinical Trial Update: Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating XNW5004 in combination with enzalutamide for metastatic castration-resistant prostate cancer is currentl…
-
CLINICAL_TRIALS research · 2025-04-17Clinical Trial Update: Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC [Phase 1]
Phase 1 study evaluating the combination of talazoparib and tazemetostat in metastatic castration-resistant prostate cancer, with the trial …
-
CLINICAL_TRIALS research · 2025-04-13Clinical Trial Update: Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating the combination of ebastine with docetaxel for metastatic castration-resistant prostate cancer; the…
-
CLINICAL_TRIALS research · 2025-04-09Clinical Trial Update: ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer [Phase 3]
Phase 3 biomarker-driven trial (ProBio) in metastatic prostate cancer is currently recruiting, enrolling patients with metastatic castration…
-
CLINICAL_TRIALS research · 2025-04-06Clinical Trial Update: EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating the radioligand therapy [161Tb]Tb-PSMA-I&T in men with metastatic castration-resistant prostate cancer…
-
CLINICAL_TRIALS research · 2025-04-06Clinical Trial Update: Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer [Phase 1, Phase 2]
A Phase 1/2 clinical trial is investigating cabazitaxel in combination with 177Lu-PSMA-617 for metastatic castration-resistant prostate canc…
-
CLINICAL_TRIALS research · 2025-03-24Clinical Trial Update: A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer [Phase 2]
Phase 2 clinical trial to evaluate the efficacy and safety of different dose regimens of an oral cabazitaxel tablet in adults with metastati…
-
CLINICAL_TRIALS research · 2025-03-19Clinical Trial Update: Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol [Phase 1, Phase 2]
This clinical trial update describes a continuation protocol for ZEN003694 in patients with metastatic castration-resistant prostate cancer …
-
CLINICAL_TRIALS research · 2025-03-12Clinical Trial Update: A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC). [Phase 3]
A Phase 3 clinical trial evaluating the efficacy and safety of HC-1119 Soft Capsules in metastatic castration-resistant prostate cancer is c…
-
CLINICAL_TRIALS research · 2025-03-10Clinical Trial Update: Phase 1 Clinical Study of GT-220F in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC) [Phase 1]
Geode Therapeutics is conducting a Phase 1 study of GT-220F for metastatic castration-resistant prostate cancer, currently not yet recruitin…
-
CLINICAL_TRIALS research · 2025-02-27Clinical Trial Update: Kuopio Lutetium-177 Study in Patients with PSMA-Positive Metastatic Prostate Cancer
This clinical trial update shows Kuopio University Hospital is recruiting for a Lutetium-177-PSMA study in PSMA PET-positive metastatic pros…
-
CLINICAL_TRIALS research · 2025-02-19Clinical Trial Update: Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) [Phase 1]
This clinical trial update reports that the Phase 1 study of HRS-5041 in metastatic castration-resistant prostate cancer is currently recrui…
-
CLINICAL_TRIALS research · 2025-02-14Clinical Trial Update: Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer [Phase 1, Phase 2]
This entry describes a Phase 1/2 trial to assess safety, tolerability, and preliminary efficacy of 161Tb-NYM032 in metastatic castration-res…
-
CLINICAL_TRIALS research · 2025-02-11Clinical Trial Update: Survival Outcomes in Metastatic Prostate Cancer in the Brazilian Population - Analysis of Individual Characteristics and Treatment Modalities in Different National Health Institutions.
This clinical trial update reports on survival outcomes for metastatic castration-resistant prostate cancer in Brazil, analyzing patient cha…
-
CLINICAL_TRIALS research · 2025-02-11Clinical Trial Update: Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer
A clinical trial evaluating the PARP inhibitor olaparib for castration-resistant prostate cancer, including patients with BRCA mutations; cu…
-
CLINICAL_TRIALS research · 2025-02-07Clinical Trial Update: A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies [Phase 2]
This clinical trial update reports on a Phase 2 study of XmAb20717 (Vudalimab) in selected advanced gynecologic and genitourinary cancers, w…
-
CLINICAL_TRIALS research · 2025-01-24Clinical Trial Update: ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer [Phase 2]
A Phase 2 randomized trial evaluating ZEN003694 in combination with enzalutamide versus enzalutamide monotherapy in metastatic castration-re…
-
CLINICAL_TRIALS research · 2025-01-14Clinical Trial Update: Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies [Phase 1]
This Phase 1 trial from Epigenetix, Inc. is evaluating a dual BET and CBP/p300 inhibitor across targeted advanced solid tumors and hematolog…